Shield Therapeutics PLC (LON:STX) had its target price hoisted by equities researchers at Canaccord Genuity from GBX 235 ($3.07) to GBX 241 ($3.15) in a research note issued on Tuesday. The firm currently has a “buy” rating on the stock. Canaccord Genuity’s price target indicates a potential upside of 51.10% from the company’s previous close.

Separately, Liberum Capital reaffirmed a “buy” rating and issued a GBX 310 ($4.05) price objective on shares of Shield Therapeutics PLC in a research note on Tuesday.

Shares of Shield Therapeutics PLC (LON:STX) traded up 2.24% during mid-day trading on Tuesday, hitting GBX 159.50. 53,770 shares of the company were exchanged. The company has a 50 day moving average of GBX 156.43 and a 200 day moving average of GBX 166.01. Shield Therapeutics PLC has a 52 week low of GBX 147.00 and a 52 week high of GBX 190.00. The company’s market capitalization is GBX 172.48 billion.

Receive News & Ratings for Shield Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics PLC and related companies with's FREE daily email newsletter.